ATG4B-Mediated DNA Repair Disruption and Leukemia Progression: Mechanistic Insights from Energy Deficiency

Study Background and Research Question

Maintenance of metabolic equilibrium and genomic stability are fundamental to cellular health, with disruptions in either process contributing to malignancy and aging. While the independent importance of metabolism and DNA repair is well established, the molecular interplay between these processes—particularly how metabolic stress influences genomic integrity—remains only partially understood. Acute myeloid leukemia (AML) is characterized by both metabolic alterations and genomic instability, yet the mechanistic bridge between these hallmarks has been elusive. The reference study (Wang et al., 2025) specifically addresses the question: How does cellular energy deficiency modulate DNA repair pathways, and what is the implication for leukemia progression?

Key Innovation from the Reference Study

The central innovation of the reference article lies in its identification of a novel signaling axis wherein energy deficiency prompts the nuclear translocation of ATG4B, a cysteine protease traditionally implicated in autophagy. Once in the nucleus, ATG4B directly interacts with PRMT1, a protein arginine methyltransferase essential for the methylation and activation of MRE11—a core component of the DNA repair machinery. This interaction inhibits PRMT1's methylation of MRE11, thereby suppressing homologous recombination repair and heightening genomic instability. Notably, this mechanism is amplified in AML cells, both patient-derived and in murine models with MLLT3-KMT2A overexpression, directly linking metabolic stress to leukemic evolution.

Methods and Experimental Design Insights

The study employed a combination of in vitro and in vivo models to dissect the molecular events underpinning energy deficiency-induced DNA repair impairment. Key experimental approaches included:

• ATP depletion to simulate cellular energy deficiency in cultured leukemia cells.
• Immunofluorescence and subcellular fractionation to monitor ATG4B localization dynamics under metabolic stress.
• Co-immunoprecipitation and proximity ligation assays to confirm the interaction between ATG4B and PRMT1.
• Mutational analysis and rescue experiments to validate the functional consequences of ATG4B translocation on DNA repair pathways.
• Assessment of DNA damage and repair through γH2AX foci counting, comet assays, and MRE11 methylation status.
• Use of AML mouse models (MLLT3-KMT2A-induced and patient-derived xenografts) to evaluate the impact on leukemia progression, cell proliferation, mutation burden, and survival.

The integration of molecular, cellular, and whole-animal models provides a robust framework for dissecting the causal relationships between metabolic stress, ATG4B activity, DNA repair fidelity, and leukemogenesis.

Core Findings and Why They Matter

Results from Wang et al. reveal several mechanistically significant findings:

• Energy deficiency triggers nuclear import of ATG4B, diverging from its canonical cytoplasmic autophagy-related role.
• Nuclear ATG4B interacts with PRMT1, resulting in decreased methylation of MRE11, a key facilitator of DNA double-strand break repair.
• Impaired PRMT1-mediated DNA repair leads to increased DNA damage and mutation accumulation, particularly in AML cells.
• Genetic or pharmacological inhibition of ATG4B restores PRMT1 activity, enhances DNA repair, suppresses leukemic cell proliferation, reduces mutation burden, and extends survival in AML mouse models.

These findings directly link metabolic stress to genomic instability via a defined molecular axis, offering a new perspective on the metabolic vulnerabilities of leukemia. The identification of ATG4B as a modulator of DNA repair under energy-deficient conditions suggests its potential as a therapeutic target for mitigating genomic instability-driven malignancy progression.

Comparison with Existing Internal Articles

Internal reviews such as "Energy Deficiency, ATG4B, and DNA Repair in AML Progression" and "Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repair in AML" both highlight the disruptive effects of metabolic stress on DNA repair in leukemia. These articles concisely summarize the mechanistic innovation—ATG4B-mediated inhibition of PRMT1-directed DNA repair—and concur that targeting this axis may provide a novel intervention point for AML. Where the reference study advances the field is through a combination of detailed subcellular localization studies, interaction validation, and comprehensive in vivo validation in both engineered and patient-derived leukemic models, thereby substantiating the therapeutic relevance of modulating ATG4B activity.

While these internal resources focus on summarizing the emerging axis, the reference article provides a more granular mechanistic and translational framework, bridging molecular events to animal-level disease outcomes and supporting the rationale for therapeutic targeting of ATG4B.

Limitations and Transferability

Despite its strengths, several limitations are inherent to the current study:

• Most data are derived from AML models; generalizability to other cancer types remains to be established.
• The precise regulatory signals governing ATG4B nuclear import under metabolic stress require further delineation.
• Potential off-target effects of ATG4B inhibition on non-leukemic tissues were not comprehensively assessed in the reported mouse models.
• While restoration of DNA repair was observed in murine and human xenograft models, clinical translation will require thorough toxicological and efficacy studies in humans.

Thus, while the ATG4B-PRMT1-MRE11 axis appears critical in AML, caution is warranted when extrapolating to other disease settings or considering systemic ATG4B inhibition as a therapeutic approach.

Protocol Parameters

• Energy deficiency induction: ATP depletion in cultured cells (e.g., using 2-deoxyglucose or oligomycin for 2-6 hours) to simulate metabolic stress conditions relevant to hematological malignancy models.
• Subcellular localization: Immunofluorescence with anti-ATG4B and nuclear markers, followed by confocal imaging for quantification of nuclear/cytoplasmic ATG4B ratio.
• PRMT1 activity assessment: Use of methylation-specific antibodies against MRE11 to determine PRMT1-mediated post-translational modification status.
• DNA repair assessment: γH2AX foci quantification and comet assay performed 1-4 hours post DNA damage induction (e.g., ionizing radiation or etoposide exposure).
• In vivo AML modeling: Transplantation of MLLT3-KMT2A-modified murine hematopoietic cells or patient-derived AML cells into immunodeficient mice; evaluate proliferation, mutation burden, and survival endpoints over 4-12 weeks.

These parameters reflect workflow elements supported by the reference study and are adaptable to allied research settings investigating DNA repair modulation under metabolic stress.

Research Support Resources

For researchers investigating antifungal drug development or designing fungal infection models, leveraging high-purity compounds with validated mechanisms is essential. Tioconazole (SKU B2051) is a well-established antifungal medication that inhibits fungal cytochrome P450 enzymes, thereby blocking the ergosterol biosynthesis pathway and compromising fungal cell membrane integrity. Tioconazole's high purity, documented solubility profiles, and robust performance in in vitro antifungal assays make it a reliable choice for studies exploring ergosterol pathway disruption and resistance mechanisms. While the primary focus of this article is on DNA repair in leukemia, these same principles of molecular mechanism and assay reproducibility apply across domains, supporting the rational design of both antifungal and anticancer research workflows.